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In the past weeks, a lot of attention has been directed to 
the article by Philip Wong and colleagues – TDP-43 Re-
pression of Nonconserved Cryptic Exons Is Compromised 
in ALS-FTD published in Science on August 7 (1). Several 
internet portals claimed that this study discovered the 
cause of amyotrophic lateral sclerosis (ALS) (2), provok-
ing a number of reactions from the public, still sensibi-
lized to ALS as a result of a recent world-wide fundraising 
event – the Ice Bucket Challenge. Some patients’ associa-
tions even organized celebration parties with the mes-
sage that “the Ice Bucket Challenge enabled scientists to 
finally solve the ALS mystery.” This was also supported by 
Wong and colleagues, who expressed gratitude for dona-
tions and invited everyone to continue to raise the bud-
get in this way (3).
ALS AND the ICe BuCket ChALLeNge
Although the Ice Bucket Challenge raised 220 million 
USD worldwide it should be stressed that this amount 
constitutes a small portion of the budget continuously 
injected into ALS research. The Ice Bucket Challenge has 
more an empathic than a scientific effect, resulting in an 
interesting social phenomenon. Similar phenomenon oc-
curred one year ago when some patients’ organizations 
announced that ALS can be cured in China (4). Without 
trying to analyze why ALS, as only one of numerous fatal 
human diseases, is surrounded by such hype, we would 
like to discuss the importance of the publication by Wong 
and colleagues.
WhAt WAS INDeeD DISCOVeReD BY WONg AND 
COLLeAgueS?
For more than a decade, it has been known that one of the 
hallmarks of ALS is accumulation of protein TDP-43. How-
ever, its link to dying of motor neurons has remained a mys-
tery. Wong and colleagues suppressed the normal function 
of protein TDP-43 and observed a surprising result: appear-
ance of abnormal strands of RNA. Indeed, when they com-
pared brains of patients affected by ALS with control pa-
tients, it become obvious that the lack of TDP43 allowed 
the production of cryptic RNA, which normally should 
not be present. Obviously, the same phenomenon occurs 
when TDP3 is not deleted, but is abnormally accumulated 
within the cells. The most valuable finding of this publica-
tion is that the authors prevented the occurrence of these 
RNA strands by a genetic engineering approach that imi-
tated the activity of wild type TDP43 and thus prevented 
cells from dying.
This important finding did not come out of nowhere. It 
was achieved thanks to the gradual progress in under-
standing of RNA-binding proteins data accumulated in 
the last two decades. Already in 1992, the concept of 
“potential for cryptic splice site usage” was intro-
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duced, which allowed scientists to predict the relative pro-
portion of exon skipping vs cryptic splice site (5). In 2009, it 
was further demonstrated that TDP-43 exhibited a high af-
finity in binding to UG-rich RNA (6). It is important to notice 
that TDP-43 binds to more than 6000 RNA targets in the 
brain, roughly 30% of the total transcriptome (7). Structur-
al TDP-43 analysis has shown that, besides containing two 
RNA recognition motifs followed by a prion-like domain, 
which is essential in determining aggregation, aggregates 
are ubiquitinated and hyperphosphorylated, which is a 
hallmark of all neurodegenerative diseases (8).
However, the intention of this study was not to discover ei-
ther the cause of TDP43 accumulation or the link to selec-
tive death of motoric neurons. In addition, their finding that 
the exons suppressed by TDP43 are not conserved, ie, that 
they differ in humans and mice, has a serious consequence 
on the applicability of mouse models for ALS research (1). 
We are still far away from understanding the cause of ALS, 
and it is highly questionable whether we will ever find a 
unique cause of all its forms. Since its seminal description 
in the 19th century, ALS has been defined and treated as 
a single neurodegenerative disorder despite broad clinical 
heterogeneity. Nowadays, it is more and more recognized 
as a heterogeneous syndrome with diverse genetic causes 
and pathology background. Genetic studies have identi-
fied abnormal repeat expansions in C9ORF72, or mutations 
in SOD1, TDP43, FUS genes responsible for most of familial 
forms of ALS. Genetic variants in genes known to cause fa-
milial ALS were found in a small fraction of sporadic pa-
tients, leaving the etiology of the sporadic form largely 
unknown (9). The genetic heterogeneity combined with 
environmental factors or patient-specific history might ex-
plain the clinical heterogeneity. Why is Stephen Hawking 
still alive with ALS when so many other patients are expect-
ed to die 2 to 5 years after diagnosis? To add to this clinical 
complexity, ALS often overlaps with progressive muscular 
atrophy, primary lateral sclerosis, frontotemporal demen-
tia, which makes the identification of a unique therapeutic 
target challenging (9). Is ALS a single disease that triggers 
a single common downstream event (ultimate death of 
upper and lower motor neurons) with many different up-
stream events (RNA processing defect, protein misfolding, 
toxic gain-of-function, protein loss-of-function) or a clini-
cal syndrome encompassing multiple subtypes of diseases 
with independent etiology and pathogenic mechanisms?
These considerations emphasize the need to innovate 
and to adopt other approaches; apart from the strat-
egy based on stem cells, which raised the highest 
interest in the last decade (10), we need approaches that 
take into account the genetic background of ALS patients. 
As ALS patient brain tissue remains largely inaccessible, in-
duced pluripotent stem cell (IPSC) technology offers the 
opportunity to generate patient-specific disease models 
in-a-dish, even when the genetic risk factors are uniden-
tified. Motor neurons or glial cells derived from these IP-
SCs might help to identify different ALS phenotypes and 
develop targeted therapies for each subtype (11). Through 
groundbreaking advances in the genetic of ALS and new 
tools allowing personalized treatment, we are about to for-
get a two-century old paradigm of treating all ALS patients 
in an identical way. Another concept which emerges as 
unavoidable is the increased use of modern neuroimag-
ing methods that now allow detecting the presence of a 
target molecule in a single cell in a living experimental ani-
mal or patient.
In conclusion, although the study by Wong and colleagues 
represents a gem of translational science, its greatest value 
is in showing us the direction in which we need to go. It 
can be expected that discovering the chain of events that 
trigger the disease onset on the molecular level will finally 
allow, combined with precise molecular visualization, the 
design the next generation of molecules with a potent and 
personalized therapeutic effect.
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